A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination With Either Docetaxel or Paclitaxel in Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer or Non-Small Cell Lung Cancer

Trial Profile

A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination With Either Docetaxel or Paclitaxel in Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer or Non-Small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 May 2017

At a glance

  • Drugs Taselisib (Primary) ; Docetaxel; Paclitaxel
  • Indications Breast cancer; Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 May 2017 Planned End Date changed from 1 Dec 2017 to 4 Oct 2017.
    • 09 May 2017 Planned primary completion date changed from 1 Dec 2017 to 4 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top